Latest Asx Disclosures News

OncoSil Medical Limited has addressed ASX concerns over delayed disclosure of PANCOSIL clinical trial results, confirming compliance with continuous disclosure obligations despite procedural oversights.

AUB Group Limited has disclosed a conditional, non-binding proposal from an EQT affiliate to acquire the company at $45 per share, following unusual trading activity and media reports.

Tasman Resources has clarified the reasons behind its recent share price jump, linking it to new drilling funding and a rise in its Eden Innovations investment value.

Multistack International Limited reported a net operating cash outflow of A$180,348 for the September quarter but maintains robust cash reserves of A$1.33 million. The company is planning a strategic disposal of its shares in Multistack Australia, signaling a potential shift in its operational focus.

PainChek Limited has confirmed FDA De Novo classification for its PainChek Adult App, promptly disclosing the material regulatory milestone to the ASX and signalling a significant step towards US market entry.

VHM Limited has clarified that a non-binding US$200 million letter of interest from the US Export-Import Bank for its Goschen project is not material to its share price, confirming full compliance with ASX disclosure rules despite recent market speculation.

Carawine Resources Limited’s shares have been suspended from trading following a Federal Court ruling that allows QGold Pty Ltd to compulsorily acquire all remaining shares it does not own.

Altitude Minerals has clarified the recent spike in its share price and trading volume, attributing the market activity to its acquisition of the Firenze silver and gold project and a successful capital raise.

Eclipse Metals has commenced mobilisation for its 2025 diamond drilling program at the Grønnedal Rare Earths Carbonatite Complex in Greenland, aiming to expand a significant rare earth mineral resource rich in critical magnet metals.

Nelson Resources has confirmed it is in confidential negotiations for a Right to Mine contract, explaining recent unusual trading activity in its shares. The company maintains compliance with ASX disclosure rules while awaiting contract finalisation.

OncoSil Medical has affirmed the materiality of the PANCOSIL Phase 1-2 trial results and detailed its compliance with ASX disclosure rules following the data presentation at CIRSE 2025.

Bounty Oil & Gas has clarified that no undisclosed information explains the recent surge in its share trading, linking activity to an ongoing Federal Court hearing on the PEP 11 project now adjourned to Sydney.